David J. Wright

PROTAC-Mediated Degradation of Bruton’s Tyrosine Kinase Is Inhibited by Covalent Binding

Degradation of proteins by PROTACs and other strategies

The re-emergence of natural products for drug discovery in the genomics era

Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction

Targeted Protein Degradation: from Chemical Biology to Drug Discovery

Drugging the p53 pathway: understanding the route to clinical efficacy

The Advantages of Targeted Protein Degradation Over Inhibition: An RTK Case Study

Structure and drug resistance of the Plasmodium falciparum transporter PfCRT

PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics

Proteasomal and lysosomal degradation for specific and durable suppression of immunotherapeutic targets

PROTAC targeted protein degraders: the past is prologue

A Pragmatic Guide to Enrichment Strategies for Mass Spectrometry–Based Glycoproteomics

Harnessing the Power of Proteolysis for Targeted Protein Inactivation

Degradation from the outside in: Targeting extracellular and membrane proteins for degradation through the endolysosomal pathway

Waste disposal—An attractive strategy for cancer therapy

The Future of Bioorthogonal Chemistry

Molecular recognition of ternary complexes: a new dimension in the structure-guided design of chemical degraders

Chemical Inhibition of ENL/AF9 YEATS Domains in Acute Leukemia

Current strategies for the design of PROTAC linkers: a critical review

Understanding Small‐Molecule Binding to MDM2: Insights into Structural Effects of Isoindolinone Inhibitors from NMR Spectroscopy

Engineering and purification of a thermostable, high-yield, variant of PfCRT, the Plasmodium falciparum chloroquine resistance transporter

Protein Degradation by In-Cell Self-Assembly of Proteolysis Targeting Chimeras